Second Malignant Neoplasms in Children and Adolescents Treated for Blood Malignancies and Solid Tumors: A Single-Center Experience of 15 Years

Abstract

Context: The occurrence of second malignancies is not rare in children treated for primary tumors. Objectives: The aim of this study was to investigate the occurrence and the outcomes of second malignancies in children and adolescents from a large tertiary pediatric hematology-oncology center. Materials and Methods: A retrospective study was performed looking into the characteristics and outcomes of second malignant neoplasms in children and adolescents treated for primary malignancies in a single center over a 15-year period. Results: Among 270 children and adolescents treated for hematological malignancies and solid tumors from 2000 to 2015, five cases of second malignancy were diagnosed including cancer of the parotid gland, renal cell carcinoma, Hodgkin’s lymphoma, thyroid carcinoma, and transitional liver cell carcinoma in patients previously treated for acute myeloid leukemia, glioblastoma multiforme, B-acute lymphoblastic leukemia, Langerhans cell histiocytosis, and medulloblastoma, respectively. Primary malignancies were treated with chemotherapy in all cases and four out of five patients had also received radiotherapy. Mean age at diagnosis of second malignancy was 10 years and 4 months. Overall survival after diagnosis of second malignancy was 80% at 12 months and 75% at 5 years. Conclusions: Close surveillance and long-term follow-up are mandatory for the identification of late effects in children treated for malignancy.

Keywords

Childhood cancer - late effects - second malignant neoplasm

• References

• 1 Ng AK, Kenney LB, Gilbert ES, Travis LB. Secondary malignancies across the age spectrum. Semin Radiat Oncol 2010; 20: 67-78
• 2 Morton LM, Onel K, Curtis RE, Hungate EA, Armstrong GT. The rising incidence of second cancers: Patterns of occurrence and identification of risk factors for children and adults. Am Soc Clin Oncol Educ Book 2014:e57-67.
• 3 Garaventa A, Gambini C, Villavecchia G, Di Cataldo A, Bertolazzi L, Pizzitola MR. et al. Second malignancies in children with neuroblastoma after combined treatment with 131I metaiodobenzylguanidine. Cancer 2003; 97: 1332-8
• 4 Duffner PK, Krischer JP, Horowitz ME, Cohen ME, Burger PC, Friedman HS. et al. Second malignancies in young children with primary brain tumors following treatment with prolonged postoperative chemotherapy and delayed irradiation: A Pediatric Oncology Group study. Ann Neurol 1998; 44: 313-6
• 5 Vázquez E, Castellote A, Piqueras J, Ortuno P, Sánchez Toledo J, Nogués P. et al. Second malignancies in pediatric patients: Imaging findings and differential diagnosis. Radiographics 2003; 23: 1155-72
• 6 Moppett J, Oakhill A, Duncan AW. Second malignancies in children: The usual suspects?. Eur J Radiol 2001; 37: 95-108
• 7 Norkin M, Uberti JP, Schiffer CA. Very late recurrences of leukemia: Why does leukemia awake after many years of dormancy?. Leuk Res 2011; 35: 139-44
• 8 Maule M, Scélo G, Pastore G, Brennan P, Hemminki K, Tracey E. et al. Risk of second malignant neoplasms after childhood leukemia and lymphoma: An international study. J Natl Cancer Inst 2007; 99: 790-800
• 9 Leung W, Ribeiro RC, Hudson M, Tong X, Srivastava DK, Rubnitz JE. et al. Second malignancy after treatment of childhood acute myeloid leukemia. Leukemia 2001; 15: 41-5
• 10 Landier W, Armenian S, Bhatia S. Late effects of childhood cancer and its treatment. Pediatr Clin North Am 2015; 62: 275-300
• 11 Friedman DL, Whitton J, Leisenring W, Mertens AC, Hammond S, Stovall M. et al. Subsequent neoplasms in 5 year survivors of childhood cancer: The Childhood Cancer Survivor Study. J Natl Cancer Inst 2010; 102: 1083 95
• 12 de Vathaire F, Scwhartz B, El Fayech C, Allodji RS, Escudier B, Hawkins M. et al. Risk of a second kidney carcinoma following childhood cancer: Role of chemotherapy and radiation dose to kidneys. J Urol 2015; 194: 1390-5
• 13 Nakano Y, Fujimaru R, Ishii K, Sakamoto H, Inoue T, Sako M. et al. Childhood pheochromocytoma in a survivor of central primitive neuroectodermal tumor. Pediatr Int 2013; 55: e100-2
• 14 Caglar K, Unal S, Cetinkaya A, Gümrük F, Yetgin S. Acute lymphoblastic leukemia as a second malignant neoplasm in a child with medulloblastoma. Pediatr Hematol Oncol 2003; 20: 535-7
• 15 Ragusa R, Russo S, Villari L, Schilirò G. Hodgkin’s disease as a second malignant neoplasm in childhood: Report of a case and review of the literature. Pediatr Hematol Oncol 2001; 18: 407-14
• 16 Geetha N, SreedeviAmma N, Kusumakumary P, Lali VS, Nair MK. Acute lymphoblastic leukemia occurring as a second malignancy: Report of a case and review of literature. Pediatr Hematol Oncol 1999; 16: 267-70
• 17 Cahan WG, Woodard HQ, Higinbotham NL, Stewart FW, Coley BL. Sarcoma arising in irradiated bone; report of 11 cases. Cancer 1948; 1: 3-29
• 18 Schrantz JL, Araoz CA. Radiation induced meningeal fibrosarcoma. Arch Pathol 1972; 93: 26-31
• 19 Zhang AY, Judson I, Benson C, Wunder JS, Ray-Coquard I, Grimer RJ. et al. Chemotherapy with radiotherapy influences time-to-development of radiation-induced sarcomas: a multicenter study. Br J Cancer 2017; 25 (117) 326-31
• 20 Kunert P, Matyja E, Prokopienko M, Marchel A. Radiation induced tumours of meninges. Report on eight cases and review of the literature. Neurol Neurochir Pol 2012; 46: 542-52
• 21 Meadows AT, Friedman DL, Neglia JP, Mertens AC, Donaldson SS, Stovall M. et al. Second neoplasms in survivors of childhood cancer: Findings from the childhood cancer survivor study cohort. J Clin Oncol 2009; 27: 2356-62
• 22 Rubnitz JE, Inaba H, Dahl G, Ribeiro RC, Bowman WP, Taub J. et al. Minimal residual disease directed therapy for childhood acute myeloid leukaemia: Results of the AML02 multicentre trial. Lancet Oncol 2010; 11: 543-52
• 23 Creutzig U, Zimmermann M, Dworzak MN, Ritter J, Schellong G, Reinhardt D. Development of a curative treatment within the AML BFM studies. Klin Padiatr 2013; 225 (01) Suppl S79-86
• 24 Pession A, Masetti R, Rizzari C, Putti MC, Casale F, Fagioli F. et al. Results of the AIEOP AML 2002/01 multicenter prospective trial for the treatment of children with acute myeloid leukemia. Blood 2013; 122: 170-8
• 25 Prasannan L, Pu A, Hoff P, Weatherly R, Castle V. Parotid carcinoma as a second malignancy after treatment of childhood acute lymphoblastic leukemia. J Pediatr Hematol Oncol 1999; 21: 535-8
• 26 Tikku G, Jain D, Kumari A, Grover R. Mucoepidermoid carcinoma of parotid as a second malignancy in acute lymphoblastic leukemia. Indian Pediatr 2015; 52: 979-80
• 27 Koh KN, Yoo KH, Im HJ, Sung KW, Koo HH, Kim HS. et al. Characteristics and outcomes of second malignant neoplasms after childhood cancer treatment: Multi center retrospective survey. J Korean Med Sci 2016; 31: 1254-61
• 28 Kraushaar G, Wiebe S. Renal cell carcinoma as a second malignant neoplasm in a patient with non syndromic hemihypertrophy and previous Wilms tumor. Pediatr Radiol 2005; 35: 1208-11
• 29 Lazarus J, Moolman C. Renal cell carcinoma as second malignancy in patient with previous Wilms tumor. Urology 2009; 74: 598-600
• 30 Neglia JP, Friedman DL, Yasui Y, Mertens AC, Hammond S, Stovall M. et al. Second malignant neoplasms in five year survivors of childhood cancer: Childhood cancer survivor study. J Natl Cancer Inst 2001; 93: 618-29
• 31 Villani A, Shore A, Wasserman JD, Stephens D, Kim RH, Druker H. et al. Biochemical and imaging surveillance in germline TP53 mutation carriers with Li Fraumeni syndrome: 11 year follow up of a prospective observational study. Lancet Oncol 2016; 17: 1295-305
• 32 Guarino S, Giusti DM, Rubini A, Favoriti P, Fioravanti C, Di Matteo FM. et al. Association between pituitary langerhans cell histiocytosis and papillary thyroid carcinoma. Clin Med Insights Case Rep 2013; 6: 197-200
• 33 Jamaati HR, Shadmehr MB, Saidi B, Khosravi A, Arab M, Mohammadi F. Langerhans cell histiocytosis of the lung and thyroid, co existing with papillary thyroid cancer. Endocr Pathol 2009; 20: 133-6
• 34 Patten DK, Wani Z, Tolley N. Solitary langerhans histiocytosis of the thyroid gland: A case report and literature review. Head Neck Pathol 2012; 6: 279-89
• 35 Moschovi M, Adamaki M, Vlahopoulos S, Rodriguez Galindo C. Synchronous and metachronous thyroid cancer in relation to Langerhans cell histiocytosis; involvement of V600E BRAF mutation?. Pediatr Blood Cancer 2015; 62: 173-4
• 36 Goldstein AM, Yuen J, Tucker MA. Second cancers after medulloblastoma: Population based results from the United States and Sweden. Cancer Causes Control 1997; 8: 865-71
• 37 Milde T, Oehme I, Korshunov A, Kopp Schneider A, Remke M, Northcott P. et al. HDAC5 and HDAC9 in medulloblastoma: Novel markers for risk stratification and role in tumor cell growth. Clin Cancer Res 2010; 16: 3240-52
• 38 Packer RJ, Zhou T, Holmes E, Vezina G, Gajjar A. Survival and secondary tumors in children with medulloblastoma receiving radiotherapy and adjuvant chemotherapy: Results of Children’s Oncology Group trial A 9961. Neuro Oncol 2013; 15: 97-103
• 39 Nomura Y, Yasumoto S, Yanai F, Akiyoshi H, Inoue T, Nibu K. et al. Survival and late effects on development of patients with infantile brain tumor. Pediatr Int 2009; 51: 337-41
• 40 Lau CS, Mahendraraj K, Chamberlain RS. Hepatocellular carcinoma in the pediatric population: A population based clinical outcomes study involving 257 patients from the surveillance, epidemiology, and end result (SEER) database (1973 2011). HPB Surg 2015; 2015: 670728
• 41 Ozcan HN, Oguz B, Salim T, Talim B, Haliloglu M. A rare malignant hepatic tumor of childhood: Transitional liver cell tumor revisited. JBR-BTR 2015; 98: 79-81
• 42 Goyal S, Singh RR, Balukrishna S, Bindra M, Backianathan S. An early and rare second malignancy in a treated glioblastoma multiforme: Is it radiation or temozolomide?. J Clin Diagn Res 2015; 9: TD05-7